Contact
Please use this form to send email to PR contact of this press release:
Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome
TO:
Please use this form to send email to PR contact of this press release:
Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome
TO: